K-ras mutation predictive significance in platinum based chemotherapeutic protocols in patients with advanced non-small cell lung cancer
Beckground/Aim. K-ras oncogene is mutated in about 20% of lung cancer. The purpose of this study was to investigate the predictive significance for therapeutic response of K-ras mutations in advanced non-small cell lung cancer (NSCLC) patients. Methods. Bronchial aspirate samples were assessed prior...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ministry of Defence of the Republic of Serbia, University of Defence, Belgrade
2009-01-01
|
| Series: | Vojnosanitetski Pregled |
| Subjects: | |
| Online Access: | http://www.doiserbia.nb.rs/img/doi/0042-8450/2009/0042-84500902149C.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849684521553756160 |
|---|---|
| author | Cvetković Gordana Plavec Goran Tomić Ilija Ilić Vesna Magić Zvonko Tatomirović Željka Novković Dobrivoje Milić Rade Karličić Vukojica |
| author_facet | Cvetković Gordana Plavec Goran Tomić Ilija Ilić Vesna Magić Zvonko Tatomirović Željka Novković Dobrivoje Milić Rade Karličić Vukojica |
| author_sort | Cvetković Gordana |
| collection | DOAJ |
| description | Beckground/Aim. K-ras oncogene is mutated in about 20% of lung cancer. The purpose of this study was to investigate the predictive significance for therapeutic response of K-ras mutations in advanced non-small cell lung cancer (NSCLC) patients. Methods. Bronchial aspirate samples were assessed prior to platinum-based chemotherapy start in 39 patients with stage IIIb or IV NSCLC. K-ras mutations at codons 12 and 13 were analyzed by single strand conformation polymorphisam (SSCP) and allele specific oligonucleozide hybridisation of polymerase chain reaction (PCR) of the patient's DNA present in bronchial aspirate. After two cycles of chemotherapy the patients were subjected to response evaluation. Results. Of 39 patients 10 (25.5%) demonstrated K-ras mutations, while 29 (74.4%) patients had not. There were no significant differences between these two groups of patients with respect to baseline patient characteristics. Partial response to the therapy had 16 (41%), no changes 14 (36%), and progressive disease 9 (23%) patients. There was a tendency to higher response rate for patients without K-ras mutations versus those with mutations, but not statistically significant (p = 0.14). Conclusion. There was no significant predictive value for therapeutic response of K-ras mutations for advanced non-small cell lung cancer. |
| format | Article |
| id | doaj-art-c11a6b91e5624de0a5e4b7f6680ef3f0 |
| institution | DOAJ |
| issn | 0042-8450 |
| language | English |
| publishDate | 2009-01-01 |
| publisher | Ministry of Defence of the Republic of Serbia, University of Defence, Belgrade |
| record_format | Article |
| series | Vojnosanitetski Pregled |
| spelling | doaj-art-c11a6b91e5624de0a5e4b7f6680ef3f02025-08-20T03:23:26ZengMinistry of Defence of the Republic of Serbia, University of Defence, BelgradeVojnosanitetski Pregled0042-84502009-01-0166214915510.2298/VSP0902149CK-ras mutation predictive significance in platinum based chemotherapeutic protocols in patients with advanced non-small cell lung cancerCvetković GordanaPlavec GoranTomić IlijaIlić VesnaMagić ZvonkoTatomirović ŽeljkaNovković DobrivojeMilić RadeKarličić VukojicaBeckground/Aim. K-ras oncogene is mutated in about 20% of lung cancer. The purpose of this study was to investigate the predictive significance for therapeutic response of K-ras mutations in advanced non-small cell lung cancer (NSCLC) patients. Methods. Bronchial aspirate samples were assessed prior to platinum-based chemotherapy start in 39 patients with stage IIIb or IV NSCLC. K-ras mutations at codons 12 and 13 were analyzed by single strand conformation polymorphisam (SSCP) and allele specific oligonucleozide hybridisation of polymerase chain reaction (PCR) of the patient's DNA present in bronchial aspirate. After two cycles of chemotherapy the patients were subjected to response evaluation. Results. Of 39 patients 10 (25.5%) demonstrated K-ras mutations, while 29 (74.4%) patients had not. There were no significant differences between these two groups of patients with respect to baseline patient characteristics. Partial response to the therapy had 16 (41%), no changes 14 (36%), and progressive disease 9 (23%) patients. There was a tendency to higher response rate for patients without K-ras mutations versus those with mutations, but not statistically significant (p = 0.14). Conclusion. There was no significant predictive value for therapeutic response of K-ras mutations for advanced non-small cell lung cancer.http://www.doiserbia.nb.rs/img/doi/0042-8450/2009/0042-84500902149C.pdfcarcinoma, non-small-cell lunggenes, rasantineoplastic combined chemotherapy protocolsplatinum compoundsprognosis |
| spellingShingle | Cvetković Gordana Plavec Goran Tomić Ilija Ilić Vesna Magić Zvonko Tatomirović Željka Novković Dobrivoje Milić Rade Karličić Vukojica K-ras mutation predictive significance in platinum based chemotherapeutic protocols in patients with advanced non-small cell lung cancer Vojnosanitetski Pregled carcinoma, non-small-cell lung genes, ras antineoplastic combined chemotherapy protocols platinum compounds prognosis |
| title | K-ras mutation predictive significance in platinum based chemotherapeutic protocols in patients with advanced non-small cell lung cancer |
| title_full | K-ras mutation predictive significance in platinum based chemotherapeutic protocols in patients with advanced non-small cell lung cancer |
| title_fullStr | K-ras mutation predictive significance in platinum based chemotherapeutic protocols in patients with advanced non-small cell lung cancer |
| title_full_unstemmed | K-ras mutation predictive significance in platinum based chemotherapeutic protocols in patients with advanced non-small cell lung cancer |
| title_short | K-ras mutation predictive significance in platinum based chemotherapeutic protocols in patients with advanced non-small cell lung cancer |
| title_sort | k ras mutation predictive significance in platinum based chemotherapeutic protocols in patients with advanced non small cell lung cancer |
| topic | carcinoma, non-small-cell lung genes, ras antineoplastic combined chemotherapy protocols platinum compounds prognosis |
| url | http://www.doiserbia.nb.rs/img/doi/0042-8450/2009/0042-84500902149C.pdf |
| work_keys_str_mv | AT cvetkovicgordana krasmutationpredictivesignificanceinplatinumbasedchemotherapeuticprotocolsinpatientswithadvancednonsmallcelllungcancer AT plavecgoran krasmutationpredictivesignificanceinplatinumbasedchemotherapeuticprotocolsinpatientswithadvancednonsmallcelllungcancer AT tomicilija krasmutationpredictivesignificanceinplatinumbasedchemotherapeuticprotocolsinpatientswithadvancednonsmallcelllungcancer AT ilicvesna krasmutationpredictivesignificanceinplatinumbasedchemotherapeuticprotocolsinpatientswithadvancednonsmallcelllungcancer AT magiczvonko krasmutationpredictivesignificanceinplatinumbasedchemotherapeuticprotocolsinpatientswithadvancednonsmallcelllungcancer AT tatomiroviczeljka krasmutationpredictivesignificanceinplatinumbasedchemotherapeuticprotocolsinpatientswithadvancednonsmallcelllungcancer AT novkovicdobrivoje krasmutationpredictivesignificanceinplatinumbasedchemotherapeuticprotocolsinpatientswithadvancednonsmallcelllungcancer AT milicrade krasmutationpredictivesignificanceinplatinumbasedchemotherapeuticprotocolsinpatientswithadvancednonsmallcelllungcancer AT karlicicvukojica krasmutationpredictivesignificanceinplatinumbasedchemotherapeuticprotocolsinpatientswithadvancednonsmallcelllungcancer |